The acquisition of 100% equity shares in the Apnar Pharma at total enterprise value is Rs. 91 crores. Of this, Rs 76 crores comprises total debt plus excepted liabilities related to the Plant to be taken over by Senores. The remaining Rs 15 crores will be paid in cash in two tranches, with 75% payable in the first tranche and 25% in the second tranche.
1st Tranche of the Transaction to be completed in current fiscal by March 2026 and 2nd tranche is expected to complete by Q2 of FY 2027.
Apnar Pharma is a pharmaceutical company primarily engaged in the business of manufacture of generic pharmaceutical formulations, having US FDA, UK-MHRA and Health Canada approved manufacturing facility near Vadodara, Gujarat.
Senores Pharmaceuticals Limited is a global, research- driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.
The companies’ current portfolio includes 46 ANDAs and 133 strengths along with a pipeline of 22 ANDAs and 52 strengths In the CMO/CDMO vertical 8 ANDAs and 24 products permitted for distribution in the USA along with a pipeline of 16 ANDAs and 57 strengths. Senores is also engaged in the development and manufacturing of complex generics certified by global food and drugs authorities and delivers generic drugs for emerging markets, catering to more than 40 countries.
The company currently has approval from regulatory bodies of more than 10 countries for its manufacturing facility in Chhatral for emerging markets with over 394 product registrations and 824 product applications. Senores also manufactures critical care injectables and Active Pharmaceutical Ingredients (“API”).
Senores has 2 manufacturing facilities for formulations – one in Atlanta, US which is USFDA approved and DEA, TAA & BAA compliant for controlled substances and government supplies & other is in Chhatral, Ahmedabad, India approved by WHO-GMP to cater to emerging markets. The company also has 2 manufacturing facilities for API in India, both located around Ahmedabad, with one in Chhatral and the other in Naroda. Senores has strong R&D capabilities to drive differentiated product portfolio across 3 R&D sites (1 in the USA and 2 in India).
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.